Tysabri® immunogenicity test-994

Test info

  
Tysabri® immunogenicity test
  
994
  
LAB994
  
MSO
  
Anti-Tysabri (Natalizumab) Ab
Natalizumab immunogenicity test
  

New drugs such as Tysabri® offer highly specific and effective therapy for Multiple sclerosis patients. However, Tysabri® loses effectiveness when patients develop antibodies to the drug. Detecting these antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy.

Specimen

  
Serum
  
  
1.0 mL
  

Immediately following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin
  3. Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
  4. Freeze within one (1) hour of sample collection
  
  
  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
  4. Freeze within one (1) hour of sample collection
  

Frozen (preferred) - 2 weeks

Refrigerated (OK) - 2 weeks

Performance

  
Viracor Eurofins (30040) via LabCorp (829191): R-NX
  
Batched
  
5 - 7 days
  

Enzyme-linked immunosorbent assay (ELISA)

Clinical and Interpretive info

  

Negative

Billing

  
83516
  
Result SOLOINC

Tracking

  
05/22/2019
  
05/22/2019